title: [First trimester screening for Down syndrome at Prima facie. A 6-year survey].
abstract: OBJECTIVE
  To evaluate the results of screening for trisomy 21 by the combined risk of first trimester (as defined by the decree of June 23, 2009) in the Prima facie structure.
  
  
  METHODS
  Single center study involving all patients that were seen for first trimester screening at Prima facie with singleton living pregnancy, not obtained by embryo donation, between 1 January 2009 and 31 December 2014.
  
  
  RESULTS
  Eighteen thousand two hundred and fifty-one patients were included, of which underwent screening for trisomy 21 by the combined risk. One thousand and forty-six (6.1%) had a calculated risk higher than 1/250. Seventy-five were affected by trisomy 21, of whom 65 in the high risk group. The sensitivity and specificity of screening are 86.7% and 94.4%. The median nuchal translucency was 0.98 MoM.
  
  
  CONCLUSIONS
  Screening for trisomy 21 by calculating the combined risk of first trimester enabled to detect 86.7% of trisomy 21 with a false positive rate of 5.6%.
authors.affiliation: Service de maternité, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France. Electronic address: philippe.roth@aphp.fr.
authors.forename: P
authors.initials: P
authors.lastname: Roth
authors.affiliation: Service de maternité, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Bernard
authors.affiliation: Laboratoire de biochimie, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Meyer
authors.affiliation: Laboratoire de biochimie, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France.
authors.forename: M-P
authors.initials: MP
authors.lastname: Beaujard
authors.affiliation: Service de maternité, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France.
authors.forename: L-J
authors.initials: LJ
authors.lastname: Salomon
authors.affiliation: Service de maternité, hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015 Paris, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Ville
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D004314:Down Syndrome / Q000175:diagnosis*; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D059785:Karyotype; D008423:Maternal Age; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D011295:Prenatal Care; D011296:Prenatal Diagnosis; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016216:Ultrasonography, Prenatal
chemical_list: D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D011266:Pregnancy-Associated Plasma Protein-A
keywords: Clarté nucale; Down syndrome; Down syndrome screening; Dépistage de la trisomie 21; Dépistage du premier trimestre; First trimester screening; Marqueurs sériques maternels; Maternal biochemical markers; Nuchal translucency; Trisomie 21